Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03573661 · ClinicalTrials.gov registry record · NA
A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers
A NA study of Palpable Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT03573661: Completed NA study of Palpable Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center.
NCT03573661 is a NA study of Palpable Breast Cancer that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03573661, a NA study of Palpable Breast Cancer, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.
Primary Outcome
Yes/No answer from Radiologist. Final measure will be % of cases rated Yes (wire deployed within the cancer on specimen mammogram).
Conditions Studied
Interventions
- DEVICE Breast Cancer Locator (BCL)
Study Locations (4)
New Hampshire
- Cheshire Medical Center - Keene
- Dartmouth Hitchcock Medical Center - Lebanon
- St. Joseph Hospital - Nashua
Massachusetts
- Lahey Hospital & Medical Center (Lahey Clinic) - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2021-04-05 |
| Phase | NA |
What the finished NCT03573661 record still lists
NCT03573661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Palpable Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Breast Cancer Locator (BCL) is the first listed.
NCT03573661 reports a single indexed study location in New Hampshire, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03573661 about?
NCT03573661 is a clinical study titled "A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers". The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, te...
What is the current status of trial NCT03573661?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-05-24. Estimated completion is 2021-04-05.
What conditions does trial NCT03573661 study?
This clinical trial studies the following conditions: Palpable Breast Cancer.
What interventions are being tested in trial NCT03573661?
The interventions under investigation include: Breast Cancer Locator (BCL) (DEVICE).
Who is sponsoring clinical trial NCT03573661?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03573661 being conducted?
This trial has 4 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03573661's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI